F Anthony Greco - JoVE Visualize

Showing results (41-50 of 127) with videos related to

Pageof 13

Sort By:

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2012

Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research instituteJohn D Hainsworth, Mark S Rubin, David R Spigel, et al.

Cancer|April 28, 2005

Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urotheliumJohn D Hainsworth, Anthony A Meluch, Sharlene Litchy, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003

Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research NetworkJohn D Hainsworth, Sharlene Litchy, John H Barton, et al.

Cancer Journal (Sudbury, Mass.)|September 29, 2011

Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortiumJohn D Hainsworth, David R Spigel, F Anthony Greco, et al.

Cancer Investigation|August 31, 2006

Docetaxel and epirubicin as first-line treatment for patients with metastatic breast cancer: a Minnie Pearl Cancer Research Network Phase II trialJohn D Hainsworth, Denise A Yardley, David R Spigel, et al.

Clinical Genitourinary Cancer|June 8, 2007

Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trialJohn D Hainsworth, Anthony A Meluch, David R Spigel, et al.

Clinical Lymphoma & Myeloma|June 16, 2009

Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research ConsortiumJohn D Hainsworth, David R Spigel, Tiffanie M Markus, et al.

Clinical Lung Cancer|July 16, 2008

A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancerSuzanne Jones, Dana Thompson, John Barton, et al.

Clinical Lung Cancer|November 6, 2003

Gefitinib in the treatment of advanced, refractory non-small-cell lung cancer: results in 124 patientsJohn D Hainsworth, Mark G Mainwaring, Melodie Thomas, et al.

Clinical Lung Cancer|August 18, 2004

A phase II trial of preoperative concurrent radiation therapy and weekly paclitaxel/carboplatin for patients with locally advanced non-small-cell lung cancerJohn D Hainsworth, James R Gray, Sharlene Litchy, et al.

Pageof 13

Showing results (41-50 of 127) with videos related to

Sort By:

Pageof 13

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2012

Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research instituteJohn D Hainsworth, Mark S Rubin, David R Spigel, et al.

Cancer|April 28, 2005

Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urotheliumJohn D Hainsworth, Anthony A Meluch, Sharlene Litchy, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003

Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research NetworkJohn D Hainsworth, Sharlene Litchy, John H Barton, et al.

Cancer Journal (Sudbury, Mass.)|September 29, 2011

Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortiumJohn D Hainsworth, David R Spigel, F Anthony Greco, et al.

Cancer Investigation|August 31, 2006

Docetaxel and epirubicin as first-line treatment for patients with metastatic breast cancer: a Minnie Pearl Cancer Research Network Phase II trialJohn D Hainsworth, Denise A Yardley, David R Spigel, et al.

Clinical Genitourinary Cancer|June 8, 2007

Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trialJohn D Hainsworth, Anthony A Meluch, David R Spigel, et al.

Clinical Lymphoma & Myeloma|June 16, 2009

Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research ConsortiumJohn D Hainsworth, David R Spigel, Tiffanie M Markus, et al.

Clinical Lung Cancer|July 16, 2008

A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancerSuzanne Jones, Dana Thompson, John Barton, et al.

Clinical Lung Cancer|November 6, 2003

Gefitinib in the treatment of advanced, refractory non-small-cell lung cancer: results in 124 patientsJohn D Hainsworth, Mark G Mainwaring, Melodie Thomas, et al.

Clinical Lung Cancer|August 18, 2004

A phase II trial of preoperative concurrent radiation therapy and weekly paclitaxel/carboplatin for patients with locally advanced non-small-cell lung cancerJohn D Hainsworth, James R Gray, Sharlene Litchy, et al.

Pageof 13